Product Description
mRNA/LNP COVID-19 Booster Vaccine. (Sourced from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387220)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HelixNano Australia Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for HN-0001](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12624000719538 | P1 |
Not yet recruiting |
COVID-19 |
2025-01-25 |
|
ACTRN12624000715572 | P1 |
Recruiting |
COVID-19 |
2024-09-06 |